Connection
Nicholas Foreman to Antineoplastic Agents, Alkylating
This is a "connection" page, showing publications Nicholas Foreman has written about Antineoplastic Agents, Alkylating.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.394 |
|
|
|
-
Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007 Apr; 48(4):403-7.
Score: 0.281
-
Foreman NK, Schissel D, Le T, Strain J, Fleitz J, Quinones R, Giller R. A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors. J Neurooncol. 2005 Jan; 71(2):181-7.
Score: 0.060
-
Yule SM, Foreman NK, Mitchell C, Gouldon N, May P, McDowell HP. High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: a dose-escalation study. J Clin Oncol. 1997 Oct; 15(10):3258-65.
Score: 0.036
-
Korones DN, Smith A, Foreman N, Bouffet E. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Pediatr Blood Cancer. 2006 Jul; 47(1):37-41.
Score: 0.017